collagenase clostridium histolyticum

Drug Overview

In the highly specialized field of Rheumatology and hand surgery, conditions involving the abnormal thickening of connective tissue can lead to debilitating physical deformities. Collagenase clostridium histolyticum is a revolutionary biological intervention designed to non-surgically break down these toughened tissues. It belongs to the Drug Category of Rheumatology (and Orthopedics/Urology) and the Drug Class of Proteolytic Enzymes.

As a Biologic therapy, this medication offers a “chemical needle” alternative to invasive surgery, specifically targeting the collagen “cords” that restrict movement or cause curvature.

• Generic Name: Collagenase clostridium histolyticum
• US Brand Name: Xiaflex
• Route of Administration: Intralesional injection (delivered directly into the affected tissue)
• FDA Approval Status: Fully FDA-approved for the treatment of Dupuytren’s Contracture with a palpable cord and Peyronie’s Disease.
  
  Read our expert overview of collagenase clostridium histolyticum, an essential Enzyme (Proteolytic) for treating xiaflex; peyronie’s and dupuytren’s. Access trusted medical information and patient resources on our hospital website.

What Is It and How Does It Work? (Mechanism of Action)

To understand how this medication works, we must examine the role of collagen in the body. Collagen is the primary structural protein in connective tissue. In conditions like Dupuytren’s contracture, the body produces an excess of Type I and Type III collagen, which forms a thick, inelastic “cord” under the skin, pulling the fingers into a permanently bent position.

Collagenase clostridium histolyticum is a mixture of two purified enzymes (AUX-I and AUX-II) derived from the bacterium Clostridium histolyticum. Its mechanism of action is highly localized:

1. Selective Lysis: Once injected directly into the collagen cord, the enzymes act as molecular “scissors.” AUX-I and AUX-II attack different segments of the collagen molecule, breaking the triple helix structure.
2. Enzymatic Digestion: The enzymes dissolve the excess collagen that makes up the cord, while largely sparing other tissues like nerves and blood vessels, which are composed of different structural proteins.
3. Mechanical Rupture: Following the injection (usually 24–72 hours later), a healthcare professional performs an “extension procedure.” This mechanical stretch snaps the weakened cord, allowing the finger or affected area to return to a straighter position.

Physiologically, this enzymatic debridement restores the range of motion without the extensive scarring and recovery time associated with surgical fasciectomy.

FDA-Approved Clinical Indications

Primary Indication

The primary indications for collagenase clostridium histolyticum are the treatment of adult patients with Dupuytren’s contracture with a palpable cord and adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30° at the start of therapy.

Other Approved & Off-Label Uses

• Cellulite Management: A version of this enzyme (Qwo) was previously approved for the treatment of moderate-to-severe cellulite in the buttocks of adult women (though market availability varies).
• Adhesive Capsulitis (Frozen Shoulder): Currently being explored in clinical trials for its ability to break down the thickened joint capsule in the shoulder.

Primary Rheumatology Indications

• Restoration of Hand Function: In Rheumatology-adjacent hand clinics, it is used to correct the “claw-like” deformity of the hand, allowing patients to perform daily tasks like shaking hands, putting on gloves, or reaching into pockets.
• Non-Surgical Correction: Provides a vital option for patients who are poor surgical candidates or those who wish to avoid the long rehabilitation associated with hand surgery.
• Connective Tissue Remodeling: Targets the underlying structural pathology of fibroproliferative disorders.

Dosage and Administration Protocols

Dosing is strictly controlled and must be administered by a physician specifically trained in the anatomy of the hand or male genitalia.

Administration Details

• Cycle Limit: For Peyronie’s, treatment consists of up to 4 treatment cycles (8 injections total).
• Procedure: For Dupuytren’s, the “finger extension procedure” is performed approximately 24 to 72 hours after the injection if the cord has not ruptured spontaneously.
• Note: The drug is supplied as a lyophilized powder that must be reconstituted with the provided sterile diluent.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical study data (2020–2026) reinforces the efficacy of enzymatic treatment over traditional “wait-and-see” approaches. In the CORD (Collagenase Option for Reduction of Dupuytren’s) trials:

• Contracture Reduction: Approximately 64% of patients achieved a reduction in primary joint contracture to within 5° of normal within 4 weeks of the last injection.
• Functional Gains: Patients showed a significant improvement in the DASH (Disabilities of the Arm, Shoulder, and Hand) score, reflecting improved physical function.
• Peyronie’s Outcomes: In the IMPRESS trials, patients treated with the enzyme saw a 34% reduction in curvature compared to 18% in the placebo group.
• 2026 Research Perspective: Recent longitudinal data shows that while recurrence can occur (as the underlying disease is chronic), the “time to recurrence” following enzyme therapy is comparable to surgical fasciectomy, with significantly lower immediate morbidity.

Safety Profile and Side Effects

Black Box Warning

Xiaflex carries a Black Box Warning for Peyronie’s Disease: Corporal Rupture (Penile Fracture). Serious injury to the penis was reported in clinical trials. For this reason, Xiaflex is only available through a restricted program called the Xiaflex REMS (Risk Evaluation and Mitigation Strategy).

Common Side Effects (>10%)

• Peripheral edema (swelling of the hand/fingers).
• Bruising (ecchymosis) and injection site hemorrhage.
• Injection site pain and tenderness.
• Lymphadenopathy (swelling of lymph nodes in the armpit or groin).

Serious Adverse Events

• Tendon Rupture: In Dupuytren’s treatment, if the drug is accidentally injected into a tendon, it can dissolve the tendon itself, requiring surgical repair.
• Severe Allergic Reactions: Anaphylaxis has been reported, as the drug is a foreign bacterial protein.
• Skin Laceration: During the extension procedure, the skin over the cord may tear.

Management Strategies: Physicians must utilize precise needle placement and avoid injecting into the flexor tendons of the finger. Local anesthesia may be used during the extension procedure.

Research Areas

Direct Clinical Connections

Contemporary research (2024–2026) is investigating the drug’s interaction with synovial fibroblasts in cases where Dupuytren’s co-exists with other stenosing tenosynovitis. Scientists are looking at how these enzymes might be refined to target B-cell memory and prevent the fibroblastic “overdrive” that causes the cords to return after treatment.

Generalization

Active clinical trials are exploring Novel Delivery Systems, such as topical or ultrasound-guided micro-injections, to reduce the risk of accidental tendon damage. There is also research into the development of Biosimilars to increase access to this high-cost Biologic.

Severe Disease & Systemic Involvement

Research is focused on the “Diathesis” or aggressive form of the disease. Scientists are evaluating if early enzymatic intervention can prevent extra-articular manifestations, such as Ledderhose disease (plantar fibromatosis in the feet), by reducing the overall systemic drive for abnormal collagen deposition.

Disclaimer: The information regarding the Xiaflex REMS program and the specific Black Box Warning for corporal rupture in the treatment of Peyronie’s disease is current as of April 2026. This therapy is highly specialized and requires administration by a clinician certified in the REMS program. Because of the risk of serious local complications—including tendon rupture and skin lacerations—it is vital to adhere strictly to post-procedural splinting and hand therapy protocols as prescribed by your specialist. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Measurement of the degree of joint contracture using a goniometer; HAQ-DI for hand function.
• Organ Function: While systemic absorption is minimal, a baseline review of coagulation (blood thinning) status is essential due to the high risk of local bruising.
• Specialized Testing: Palpation to confirm the presence of a “palpable cord”—if no cord is felt, the drug cannot be safely injected.
• Screening: Review of anticoagulants (like warfarin) which may need to be paused.

Monitoring and Precautions

• Vigilance: Monitoring for signs of tendon injury (inability to flex the finger) following the procedure.
• Lifestyle:
  • Splinting: Use of a nighttime extension splint for several months after the procedure is critical for success.
  • Hand Therapy: Specific “tendon gliding” exercises to maintain the new range of motion.
  • Smoking Cessation: Smoking is linked to a higher risk of Dupuytren’s recurrence and poor wound healing.
• “Do’s and Don’ts”
  • DO keep the hand elevated for 48 hours after injection to reduce swelling.
  • DO follow the prescribed finger exercise program religiously.
  • DON’T attempt to snap the cord yourself or perform heavy lifting until cleared by your doctor.
  • DON’T ignore sudden, severe pain or a “popping” sound that occurs outside of the extension procedure.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a board-certified rheumatologist, hand surgeon, or urologist before undergoing this procedure. Collagenase clostridium histolyticum carries risks of serious local tissue damage and must only be administered by certified healthcare professionals.